Medtronic regains the top spot, Abbott surges, and Johnson & Johnson unveils its big move: Unveiling the Q2 financial reports of global cardiovascular giants

【Answer 1】 Turning to Abbott, its diagnostic segment delivered a standout performance—‘a lone rider rescuing the entire business’—driven by strategic acquisitions. Abbott’s Q2 total revenue reached $12.593 billion, up 13.0% year-on-year. Within its business portfolio, medical devices remain its anchor—$5.853 billion (+9.0%). Yet the most explosive variable this quarter came from diagnostics: $3.092 billion, soaring 42.3% year-on-year. The growth engine was the industry-shaking acquisition of Exact Sciences on March 23—Abbott’s bold bet. In the财报, the newly established ‘Cancer Diagnostics’ segment generated $919 million in a single quarter. This figure truly qualifies as ‘a lone rider rescuing the entire business’: excluding this newly consolidated contribution, Abbott’s legacy diagnostics business saw virtually zero growth. Core laboratory diagnostics grew modestly by 4.40%, while rapid/molecular diagnostics declined 7.30%—dragged down by waning demand for respiratory testing. Yet behind that $919 million lies a far grander ambition: $890 million originated from the U.S. market, with only $29 million contributed internationally. This means the high-barrier, blue-ocean market for early cancer screening remains largely untapped across vast international markets—including China. Source: Abbott Q2 2026 Financial Report Cardiovascular business remains Abbott’s ‘grand finale’. Electrophysiology (EP) ($861 million, +14.0%) is the undisputed dark horse. A subtle but strategically significant accounting detail in the财报 stands out: Abbott moved its left atrial appendage closure device, Amulet, from the Structural Heart division into the EP division at the start of the year—transferring approximately $55 million in quarterly revenue. This signals Abbott’s commercial push to integrate a complete therapeutic loop: mapping + ablation + occlusion. Meanwhile, cardiac rhythm management ($743 million, +10.4%), heart failure ($401 million, +9.0%), and vascular ($803 million, +6.1%) all posted steady growth. In diabetes care, CGM products drove segment revenue to $2.188 billion (+10.5%), and its first dual-mode glucose-and-ketone sensor, Libre Duo, has secured CE Mark approval. Source: Abbott Q2 2026 Financial Report Finally, Johnson & Johnson leveraged Shockwave to stage a comeback—solid performance concealing ‘new possibilities’. J&J’s Q2 total revenue stood at $25.31 billion (+6.6%). After exceeding expectations, the company promptly raised its full-year revenue and EPS guidance. Its Innovative Pharmaceuticals segment remains the primary growth engine ($16.384 billion, +7.8%), yet its MedTech segment ($8.926 billion, +4.5%) also held firm. Among MedTech’s four major divisions, Cardiovascular ($2.404 billion, +4.0%) offered the most compelling narrative. Electrophysiology ($1.533 billion, +4.4%) remains its crown jewel; its Dual Energy THERMOCOOL SMARTTOUCH SF ablation catheter recently received FDA approval. What truly enabled J&J’s cardiovascular ‘comeback against the wind’ was Shockwave. Acquired in 2024 for $13.1 billion, this new business delivered $335 million in global revenue this quarter—a robust 14.6% year-on-year increase.

Collective surge among global cardiovascular giants in Q1 2026: J&J takes the lead, PFA growth hits 50%—the 'antifragile' logic of medical devices

【Answer 2】 In Q1 2026, the global medical device industry delivered a remarkably dynamic performance. While China’s volume-based procurement (VBP) policies continue cutting deep into stents, balloons, pacemakers, and even cardiac electrophysiology (EP), industry consensus had braced for an impending ‘winter’. Yet the three cardiovascular giants collectively staged a counter-cyclical, explosive surge: Johnson & Johnson MedTech topped the global device rankings with $8.636 billion in revenue; its cardiovascular business surged 13% year-on-year to $2.377 billion. Medtronic’s cardiac ablation solutions approached 50% growth, with its pulsed field ablation (PFA) catheters accelerating global rollout. Abbott’s cardiovascular revenue hit $3.216 billion (+13.2% YoY), with cardiac rhythm management soaring 17%. Note: Abbott’s figures include only Medical Devices + Diagnostics; J&J’s reflect Medical Devices only. The paradox in these numbers lies in the rare ‘scissors effect’ between policy pressure and technological breakthrough. J&J candidly acknowledged on its earnings call that China’s upcoming EP device procurement will impact H2 results; Abbott admitted absorbing ~$400 million in VBP-related revenue pressure in China; Medtronic’s neurovascular business was likewise affected by VBP. Yet rather than declining, the three giants’ revenue curves continued climbing—propelled by innovation in PFA, leadless pacemakers, and intravascular lithotripsy (IVL). This is no simple ‘growth miracle’, but rather a concentrated manifestation of the medical device industry’s ‘antifragile’ logic: when mature products are forced into volume-for-price trade-offs under procurement, innovative technologies instead gain steeper clinical adoption curves and more urgent commercialization windows. Policy turbulence did not drown the giants—it accelerated the industry’s structural shift from ‘scale-driven dividends’ to ‘technology-driven dividends’. 01. Top-tier global cardiovascular ‘report cards’ released Recently, Johnson & Johnson and Abbott released their Q1 2026 results (Medtronic published its report in July 2025). J&J MedTech ranked #1 globally in Q1 2026 medical devices, with Medtronic following closely and Abbott securing third place at $7.719 billion. Looking specifically at cardiovascular, Medtronic reported $3.285 billion (+9.3% YoY); Abbott, $3.216 billion (+13.2% YoY); and J&J MedTech, $2.377 billion (+13% YoY). Pulsed Field Ablation (PFA) remains the hottest topic in cardiovascular—J&J’s Varipulse Pro received CE Mark and launched in Europe in Q1 2026; Medtronic likewise advanced rapidly in PFA, with its cardiac ablation solutions growing 50% YoY. Johnson & Johnson: Strong cardiovascular performance, growth across all three businesses In Q1 2026, J&J’s total revenue reached $24.062 billion, up 9.9% YoY—exceeding Wall Street’s prior expectation of $23.61 billion. Breakdown: Innovative Pharmaceuticals: The main growth engine, accounting for over 64% of sales—$15.426 billion, up 11.2% YoY; MedTech: $8.636 billion, up 7.7% YoY. Growth was primarily driven by electrophysiology products, Abiomed, Shockwave, and orthopedic trauma devices.

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

18 hours ago

Johnson & Johnson reported third-quarter profits exceeding expectations, driven by strong Tremfya sales, though geopolitical tensions in the Middle East hindered medical device revenue growth. The company raised its full-year sales forecast despite international market challenges.

reuters

2026-04-14

Johnson & Johnson First-Quarter Profit Beats Estimates Despite Stelara Sales Decline

2026-06-05

J&J Wins Lawsuit Alleging Talc Caused Three Women's Cancer

2026-07-15

J&J Quarterly Earnings Beat Wall Street Estimates on Strength of Medicines Unit

2026-10-13

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

FAQ